Cerebral Aneurysm Market

Market Overview:

The 7 major cerebral aneurysm markets are expected to exhibit a CAGR of 7.06% during 2024-2034.

The cerebral aneurysm market has been comprehensively analyzed in IMARC's new report titled "Cerebral Aneurysm Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". A cerebral aneurysm, also known as an intracranial or brain aneurysm, is an abnormal bulging or ballooning in the wall of a blood vessel within the brain. These may vary in size and shape, ranging from small and unruptured to large and potentially life-threatening. Unruptured aneurysms often do not cause symptoms, but if they grow larger or press on surrounding structures, they can lead to localized headaches, eye pain or vision changes, dilated pupils, facial pain, cranial nerve dysfunction, etc. On the other hand, a ruptured cerebral aneurysm can result in a sudden, severe headache, neck pain or stiffness, nausea and vomiting, sensitivity to light, changes in mental status or consciousness, seizures, etc. The diagnosis of a cerebral aneurysm typically involves a combination of medical history evaluation, physical examination, and imaging studies. Numerous imaging techniques, such as computed tomography angiography (CTA), magnetic resonance angiography (MRA), cerebral angiography, etc., are commonly used to visualize the blood vessels in the brain and identify an aneurysm. Additional diagnostic tests, including lumbar punctures and neurological assessments, may be performed to evaluate the presence of subarachnoid hemorrhage or associated neurological deficits.

The increasing cases of weakening or thinning of the arterial walls in the brain, which create a bulging or ballooning of the blood vessel, are primarily driving the cerebral aneurysm market. In addition to this, the rising incidence of several associated risk factors, including advancing age, high blood pressure, head trauma, coexisting medical conditions like arteriovenous malformations, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of antiplatelet medications, such as aspirin and clopidogrel, to prevent platelets from clumping together and forming blood clots is further bolstering the market growth. Apart from this, the inflating application of intrasaccular devices, including flow disruptors and embolic coils with complex shapes, for promoting blood clotting and occluding the aneurysm sac in order to reduce the likelihood of rupture is acting as another significant growth-inducing factor. Additionally, the ongoing advancements in imaging technology, such as the introduction of high-resolution 3D rotational angiography and cone-beam CT, which provide detailed anatomical information and aid in treatment planning, are expected to drive the cerebral aneurysm market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the cerebral aneurysm market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for cerebral aneurysm and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cerebral aneurysm market in any manner.

Key Highlights:

• The global prevalence of cerebral aneurysms is around 3.2%, with a mean age of 50 and a 1:1 gender ratio.
• This ratio shifts considerably beyond age 50, with female preponderance nearing 2:1, which is assumed to be owing to decreasing circulating estrogen, which causes a decrease in the collagen composition of vascular tissue.
• Ruptured aneurysms are less common, occurring in approximately ten per 100,000 instances.
• Most aneurysms form after the age of 40; however, they can also occur in children.
• African-Americans and Hispanics have twice the risk of having a ruptured cerebral aneurysm as Caucasians.
• The overall mortality rate for ruptured cerebral aneurysms is estimated to be as high as 65%.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the cerebral aneurysm market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the cerebral aneurysm market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current cerebral aneurysm marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
      

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the cerebral aneurysm market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the cerebral aneurysm market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the cerebral aneurysm market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of cerebral aneurysm across the seven major markets?
• What is the number of prevalent cases (2018-2034) of cerebral aneurysm by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of cerebral aneurysm by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with cerebral aneurysm across the seven major markets?
• What is the size of the cerebral aneurysm patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of cerebral aneurysm?
• What will be the growth rate of patients across the seven major markets?
   

Cerebral Aneurysm: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for cerebral aneurysm drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cerebral aneurysm market?
• What are the key regulatory events related to the cerebral aneurysm market?
• What is the structure of clinical trial landscape by status related to the cerebral aneurysm market?
• What is the structure of clinical trial landscape by phase related to the cerebral aneurysm market?
• What is the structure of clinical trial landscape by route of administration related to the cerebral aneurysm market?